Correlation Between Microsoft and Genmab AS
Can any of the company-specific risk be diversified away by investing in both Microsoft and Genmab AS at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and Genmab AS into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and Genmab AS, you can compare the effects of market volatilities on Microsoft and Genmab AS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of Genmab AS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and Genmab AS.
Diversification Opportunities for Microsoft and Genmab AS
Good diversification
The 3 months correlation between Microsoft and Genmab is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and Genmab AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genmab AS and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with Genmab AS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genmab AS has no effect on the direction of Microsoft i.e., Microsoft and Genmab AS go up and down completely randomly.
Pair Corralation between Microsoft and Genmab AS
Given the investment horizon of 90 days Microsoft is expected to generate 0.33 times more return on investment than Genmab AS. However, Microsoft is 3.0 times less risky than Genmab AS. It trades about 0.15 of its potential returns per unit of risk. Genmab AS is currently generating about -0.04 per unit of risk. If you would invest 40,955 in Microsoft on September 2, 2024 and sell it today you would earn a total of 1,391 from holding Microsoft or generate 3.4% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Microsoft vs. Genmab AS
Performance |
| Timeline |
| Microsoft |
| Genmab AS |
Microsoft and Genmab AS Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Microsoft and Genmab AS
The main advantage of trading using opposite Microsoft and Genmab AS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, Genmab AS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will offset losses from the drop in Genmab AS's long position.| Microsoft vs. Palo Alto Networks | Microsoft vs. Uipath Inc | Microsoft vs. Block Inc | Microsoft vs. Adobe Systems Incorporated |
| Genmab AS vs. Inhibikase Therapeutics | Genmab AS vs. Purple Biotech | Genmab AS vs. Synaptogenix | Genmab AS vs. Legend Biotech Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Complementary Tools
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |